Waters Corporation (WAT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Waters Corporation (WAT) Healthcare & Pipeline Overview

Waters Corporation stands out in the healthcare sector by delivering advanced analytical solutions through its high-performance liquid chromatography and mass spectrometry systems, catering to a wide range of industries including pharmaceuticals, environmental testing, and life sciences research.

What Is the Investment Thesis for WAT?

Waters Corporation's robust market position is underscored by its P/E ratio of 69.9 and a profit margin of 11.9%. The company's focus on high-performance liquid chromatography and mass spectrometry positions it well for growth, particularly in the pharmaceutical and life sciences sectors, which are projected to expand significantly. Key growth catalysts include the increasing demand for analytical solutions in drug discovery and environmental testing, as well as the company's commitment to innovation in thermal analysis and rheometry. With a gross margin of 55.0%, Waters demonstrates strong operational efficiency, enhancing its ability to invest in R&D and expand its market share. The absence of a dividend reflects a reinvestment strategy aimed at long-term growth, which could yield substantial returns for investors as the healthcare market continues to evolve.

Based on FMP financials and quantitative analysis

WAT Key Highlights

Market capitalization of $30.3B reflects strong investor confidence in Waters Corporation's growth potential.

• P/E ratio of 69.9 indicates a premium valuation, driven by high demand for analytical solutions.
• Profit margin of 11.9% showcases effective cost management and operational efficiency.
• Gross margin of 55.0% exceeds industry averages, highlighting Waters' competitive advantage in pricing and product quality.
• Beta of 1.20 suggests moderate volatility, aligning with market trends in the healthcare sector.

Who Are WAT's Competitors?

WAT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are WAT's Key Strengths?

Leading position in high-performance liquid chromatography and mass spectrometry.

• Strong gross margin of 55.0%, indicating operational efficiency.
• Diverse product portfolio catering to multiple industries.
• Established global presence with a broad customer base.

What Are WAT's Weaknesses?

High P/E ratio of 69.9 may indicate overvaluation concerns.

• Dependence on a limited number of key product lines.
• No dividend yield, which may deter income-focused investors.

What Could Drive WAT Stock Higher?

WAT catalyst: Launch of new high-performance liquid chromatography systems expected to enhance product offerings and market share.

• Continued investment in R&D to drive innovation and maintain competitive advantage in analytical solutions.
• Expansion into emerging markets to capture new customer segments and increase revenue streams.

What Are the Key Risks for WAT?

Rich valuation — a P/E of 69.9 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Regulatory changes could impact product approval timelines and market access.
• Intense competition may pressure pricing and market share.
• Economic downturns could reduce customer spending on analytical solutions.

What Are the Growth Opportunities for WAT?

• Growth opportunity 1: The global mass spectrometry market is projected to reach $5.5 billion by 2027, growing at a CAGR of 7.5%. Waters Corporation's advanced MS technology positions it to capture market share as demand increases for drug discovery and environmental testing solutions.
• Waters' innovative thermal analysis instruments will allow the company to tap into this expanding market, enhancing its product offerings.
• Growth opportunity 3: The increasing focus on personalized medicine is driving demand for high-performance liquid chromatography systems. With the global market for HPLC projected to grow at a CAGR of 6% through 2026, Waters is strategically positioned to benefit from this trend.
• Growth opportunity 4: Expansion into emerging markets, particularly in Asia and South America, presents significant growth potential. As healthcare infrastructure improves in these regions, Waters can leverage its expertise to establish a strong presence and capture new customer segments.
• Growth opportunity 5: Collaborations with academic institutions and research organizations can enhance Waters' product development and innovation capabilities. By partnering on research initiatives, the company can drive advancements in analytical technologies that meet evolving market needs.

What Threats Does WAT Face?

• Intense competition from established players and new entrants.
• Regulatory changes impacting product development and approvals.
• Economic downturns affecting customer budgets for analytical solutions.

What Are WAT's Competitive Advantages?

• Strong brand reputation built on decades of innovation and quality.
• Extensive patent portfolio protecting proprietary technologies.
• Established relationships with key customers in the pharmaceutical and life sciences sectors.
• High barriers to entry due to the complexity of analytical instrumentation.
• Robust R&D capabilities driving continuous product innovation.

What Does WAT Do?

Founded in 1958, Waters Corporation has evolved into a premier specialty measurement company, headquartered in Milford, Massachusetts. The company operates through two primary segments: Waters and TA, focusing on providing analytical workflow solutions across Asia, the Americas, and Europe. Waters designs, manufactures, and services high-performance and ultra-performance liquid chromatography systems, along with mass spectrometry (MS) technology systems. Its product portfolio encompasses chromatography columns, consumable products, and post-warranty service plans, ensuring comprehensive support for its customers. Additionally, Waters develops thermal analysis, rheometry, and calorimetry instruments, which are essential for predicting the stability and suitability of various substances, including pharmaceuticals, polymers, and metals. The company's MS technology instruments play a critical role in drug discovery and development, clinical trial testing, and environmental analysis, making them invaluable in the healthcare and life sciences sectors. Waters caters to a diverse clientele, including life science, pharmaceutical, biochemical, industrial, and governmental customers, who rely on its products for research and development, quality assurance, and laboratory applications. With a workforce of approximately 7,600 employees, Waters Corporation continues to lead in innovation and quality within the analytical instrumentation market.

What Products and Services Does WAT Offer?

• Design and manufacture high-performance liquid chromatography systems.
• Develop and sell mass spectrometry technology systems and support products.
• Provide thermal analysis, rheometry, and calorimetry instruments.
• Offer consumable products and post-warranty service plans.
• Develop software-based products that interface with analytical instruments.
• Serve diverse sectors including pharmaceuticals, environmental testing, and life sciences.

How Does WAT Make Money?

• Generate revenue through the sale of analytical instruments and systems.
• Offer consumable products that complement core instrumentation sales.
• Provide post-warranty service plans for ongoing customer support.
• Develop and license software solutions that enhance instrument functionality.
• Engage in R&D to innovate and expand product offerings.

What Industry Does WAT Operate In?

The medical diagnostics and research industry is experiencing significant growth, driven by advancements in technology and increasing demand for precise analytical solutions. The global market for analytical instruments is projected to expand as regulatory requirements in pharmaceuticals and environmental testing become more stringent. Waters Corporation is well-positioned within this landscape, leveraging its expertise in chromatography and mass spectrometry to meet the evolving needs of its customers. Key competitors include Mettler-Toledo International Inc. (MTD), DexCom, Inc. (DXCM), Quest Diagnostics Incorporated (DGX), STERIS plc (STE), and Labcorp Holdings Inc. (LH), each vying for market share in this dynamic sector.

Who Are WAT's Key Customers?

• Pharmaceutical companies conducting drug discovery and development.
• Life science research institutions and laboratories.
• Environmental testing agencies and organizations.
• Biochemical and industrial companies requiring analytical solutions.
• Governmental and academic institutions involved in research.

Company Profile

Waters Corporation operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Milford, US. The company is led by CEO Udit Batra. WAT has traded publicly since 1995.

Return on equity for Waters Corporation stands at 1.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.7%, showing how much profit it generates from its asset base. WAT trades at a trailing price-to-earnings ratio of 69.92, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.86 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.4%, the inverse of the P/E and a quick read on earnings relative to price.

WAT Valuation & Market Position

With a $30.3B market cap, Waters Corporation sits in the large-cap segment of the market. Relative to its peer group, WAT's quantitative score of 63/100 is below the peer average of 81/100.

Quarterly Financial Performance: Waters Corporation

Revenue for Waters Corporation came in at $1.65B during Q3 2026, a 29.8% improvement versus the preceding quarter. The company recorded a net loss of $136.0M, with diluted EPS of $-1.39. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, WAT averaged $1.00 in diluted EPS.

Waters Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.81 places it in the grey zone, a middle ground that warrants monitoring.

Waters Corporation has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 4.7% above estimates on average.

Wall Street analysts project Waters Corporation revenue of about $6.46B for fiscal 2026, with EPS near $14.58. The estimate reflects 17 contributing analysts.

Over the past six months, Waters Corporation insiders filed 30 SEC Form 4 transactions — 6 sales and 24 purchases. On net that is roughly 48K shares acquired (about $12.4M) — insiders putting money in tends to read as conviction.

WAT Financials

WAT Latest News

WAT Analyst Consensus

WAT MoonshotScore

Common Questions About WAT (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources